| 000 | 01761 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515130654.0 | ||
| 264 | 0 | _c20090109 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.00364-08 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOjo, Kayode K | |
| 245 | 0 | 0 |
_aGlycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cOct 2008 |
||
| 300 |
_a3710-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBase Sequence |
| 650 | 0 | 4 |
_aDNA Primers _xgenetics |
| 650 | 0 | 4 |
_aDNA, Protozoan _xgenetics |
| 650 | 0 | 4 | _aGenes, Protozoan |
| 650 | 0 | 4 |
_aGlycogen Synthase Kinase 3 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aRNA Interference |
| 650 | 0 | 4 |
_aRecombinant Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSpecies Specificity |
| 650 | 0 | 4 |
_aTrypanosoma brucei brucei _xdrug effects |
| 650 | 0 | 4 |
_aTrypanosomiasis, African _xdrug therapy |
| 700 | 1 | _aGillespie, J Robert | |
| 700 | 1 | _aRiechers, Aaron J | |
| 700 | 1 | _aNapuli, Alberto J | |
| 700 | 1 | _aVerlinde, Christophe L M J | |
| 700 | 1 | _aBuckner, Frederick S | |
| 700 | 1 | _aGelb, Michael H | |
| 700 | 1 | _aDomostoj, Mathias M | |
| 700 | 1 | _aWells, Susan J | |
| 700 | 1 | _aScheer, Alexander | |
| 700 | 1 | _aWells, Timothy N C | |
| 700 | 1 | _aVan Voorhis, Wesley C | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 52 _gno. 10 _gp. 3710-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.00364-08 _zAvailable from publisher's website |
| 999 |
_c18124851 _d18124851 |
||